U. Axelsson, R. Bachmann, and J. Hällén, Frequency of Pathological Proteins (M-components) in 6,995 Sera from an Adult Population, Acta Medica Scandinavica. 24 avr, vol.179, issue.2, pp.235-282, 2009.

R. A. Kyle, M. T. Terry, and V. Rajkumar, Prevalence of Monoclonal Gammopathy of Undetermined Significance, n engl j med, vol.8, 2006.

D. Adams, P. Lozeron, M. Théaudin, C. Adam, and C. Lacroix, Neuropathies périphériques au cours des dysglobulinémies, EMC-Neurologie. janv, vol.8, issue.3, pp.1-14, 2011.

, European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision, Journal of the Peripheral Nervous System. mars, vol.15, issue.1, pp.1-9, 2010.

E. Nobile-orazio, S. Barbieri, L. Baldini, P. Marmiroli, M. Carpo et al., Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies, Acta Neurologica Scandinavica, vol.85, issue.6, pp.383-90, 1992.

K. J. Kyle, R. A. O'brien, P. C. Dyck, and P. J. , Prevalence of monoclonal protein in peripheral neuropathy, Neurology, 1981.

K. B. Yeung, P. K. Thomas, R. King, H. Waddy, R. G. Will et al., The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia: Comparative clinical, immunological and nerve biopsy findings, Journal of Neurology, vol.238, issue.7, pp.383-91, 1991.

S. Gosselin, R. A. Kyle, and P. J. Dyck, Neuropathy associated with monoclonal gammopathies of undetermined significance, Annals of Neurology. juill, vol.30, issue.1, pp.54-61, 1991.

J. M. Vallat, M. O. Jauberteau, D. Bordessoule, C. Yardin, P. M. Preux et al., Link between peripheral neuropathy and monoclonal dysglobulinemia: a study of 66 cases, Journal of the Neurological Sciences. mai, vol.137, issue.2, pp.124-154, 1996.

R. Diaz-arrastia, D. S. Younger, and L. Hair, Neurolymphomatosis: a clinicopathologic syndrome reemerges, Neurology, 1992.
DOI : 10.1212/wnl.42.6.1136

C. Meier, Polyneuropathy in paraproteinaemia, Journal of Neurology. août, vol.232, issue.4, pp.204-218, 1985.
DOI : 10.1007/bf00313781

H. Franssen and N. C. Notermans, Length dependence in polyneuropathy associated with IgM gammopathy, Annals of Neurology. févr, vol.59, issue.2, pp.365-71, 2006.
DOI : 10.1002/ana.20785

Z. Simmons, J. W. Albers, M. B. Bromberg, and E. L. Feldman, Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy Comparison of patients without and with monoclonal gammopathy, Neurology, 1993.

N. C. Notermans, J. Wokke, H. M. Lokhorst, H. Franssen, Y. Van-der-graaf et al., Polyneuropathy associated with monoclonal gammopathy of undetermined significance: A prospective study of the prognostic value of clinical and laboratory abnormalities, Brain, vol.117, issue.6, pp.1385-93, 1994.

H. J. Willison, The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies, Brain, vol.124, issue.10, pp.1968-77, 2001.

A. Dispenzieri, POEMS syndrome: Update on diagnosis, risk-stratification, and management: POEMS syndrome, American Journal of Hematology, vol.90, issue.10, pp.951-62, 2015.
DOI : 10.1002/ajh.24171

URL : https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.24171

D. Adams, P. Lozeron, M. Theaudin, C. Denier, O. Fagniez et al., Varied patterns of inaugural light-chain (AL) amyloid polyneuropathy: a monocentric study of 24 patients, Amyloid. juin, vol.18, issue.sup1, pp.98-100, 2011.

R. Nemni, M. Corbo, R. Fazio, A. Quattrini, G. Comi et al., CRYOGLOBULINAEMIC NEUROPATHY: A CLINICAL, MORPHOLOGICAL AND IMMUNOCY TOCHEMICAL STUDY OF 8 CASES, Brain, vol.111, issue.3, pp.541-52, 1988.

N. Latov, W. Sherman, R. Nemni, and G. Galassi, Plasma-Cell Dyscrasia and Peripheral Neuropathy with a Monoclonal Antibody to Peripheral-Nerve Myelin, The New England Journal Of Medecine, 1980.
DOI : 10.1056/nejm198009113031105

P. E. Braun, D. E. Frail, and N. Latov, Myelin-Associated Glycoprotein Is the Antigen for a Monoclonal IgM in Polyneuropathy, Journal of Neurochemistry, vol.39, issue.5, pp.1261-1266, 1982.

I. S. Smith, S. N. Kahn, B. W. Lacey, R. King, R. A. Eames et al., CHRONIC DEMYELINATING NEUROPATHY ASSOCIATED WITH BENIGN IGM PARAPROTEINAEMIA. Brain, vol.106, issue.1, pp.169-95, 1983.

E. Ellie, A. Vital, A. Steck, J. Boiron, C. Vital et al., Neuropathy associated with ?benign? anti-myelin-associated glycoprotein IgM gammopathy: Clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases, Journal of Neurology, vol.243, issue.1, pp.34-43, 1995.

L. Baldini, E. Nobile-orazio, A. Guffanti, S. Barbieri, M. Carpo et al., Peripheral neuropathy in IgM monoclonal gammopathy and wäldenstrom's macroglobulinemia: A frequent complication in elderly males with low MAG-reactive serum monoclonal component, American Journal of Hematology. janv, vol.45, issue.1, pp.25-31, 1994.

E. Nobile-orazio, E. Manfredini, M. Carpo, N. Meucci, S. Monaco et al., Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy, Annals of Neurology, vol.36, issue.3, pp.416-440, 1994.

M. Campagnolo, R. Zambello, E. Nobile-orazio, L. Benedetti, G. A. Marfia et al., IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy, Neurosurgery & Psychiatry. déc, vol.88, issue.12, pp.1094-1101, 2017.

B. Chassande, J. L?ger, A. B. Younes-chennoufi, D. Bengoufa, T. Maisonobe et al., Peripheral neuropathy associated with IgM monoclonal gammopathy: Correlations between Mprotein antibody activity and clinical/electrophysiological features in 40 cases, Muscle & Nerve. janv, vol.21, issue.1, pp.55-62, 1998.

K. B. Yeung, P. K. Thomas, R. King, H. Waddy, R. G. Will et al., The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia: Comparative clinical, immunological and nerve biopsy findings, Journal of Neurology, vol.238, issue.7, pp.383-91, 1991.

E. Nobile-orazio, P. Marmiroli, L. Baldini, and G. Spagnol, Peripheral neuropathy in macroglobulinemia Incidence and antigen-specificity of M proteins, Neurology, 1987.

O. Decaux, H. Avet-loiseau, and B. Grosbois, Facteurs pronostiques des gammapathies monoclonales de signification indéterminée, vol.14, p.11, 2008.

R. A. Kyle, Monoclonal gammapathy of undetermined significance and solitary plasmocytoma, Hematology/Oncology Clinics of North America. févr, vol.11, issue.1, pp.71-87, 1997.

R. A. Kyle, Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma, European Journal of Haematology, vol.43, issue.S51, pp.70-75, 1989.

R. A. Kyle, D. R. Larson, T. M. Therneau, A. Dispenzieri, S. Kumar et al., Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management, 33. on behalf of the International Myeloma Working Group22, vol.378, pp.1121-1128, 2010.

M. A. Gertz, Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management: Update on Waldenström macroglobulinemia, American Journal of Hematology. avr, vol.90, issue.4, pp.346-54, 2015.

T. Levine, Peripheral neuropathies in Waldenstrom's macroglobulinaemia, Neurosurgery & Psychiatry. 1 févr, vol.77, issue.2, pp.224-232, 2006.

P. Morel, A. Duhamel, P. Gobbi, M. A. Dimopoulos, M. V. Dhodapkar et al., International prognostic scoring system for Waldenstrom macroglobulinemia, Blood. 30 avr, vol.113, issue.18, pp.4163-70, 2009.

R. Fonseca, S. Hayman, and . Waldenström, British Journal of Haematology. sept, vol.138, issue.6, pp.700-720, 2007.

R. H. Quarles, Myelin-associated glycoprotein (MAG): past, present and beyond, Journal of Neurochemistry. 4 janv, vol.0, issue.0, p.070214184024009, 2007.

M. Keita, L. Magy, A. Heape, L. Richard, M. Piaser et al., Immunocytological Studies of LMAG Expression Regulation during Myelination of Embryonic Brain Cell Cocultures, Developmental Neuroscience, vol.24, issue.6, pp.495-503, 2002.

R. H. Quarles and M. D. Weiss, Autoantibodies associated with peripheral neuropathy, Muscle & Nerve. juill, vol.22, issue.7, pp.800-822, 1999.

R. L. Schnaar and P. Lopez, Myelin-associated glycoprotein and its axonal receptors, Journal of Neuroscience Research, vol.87, issue.15, pp.3267-76, 2009.

J. Huang, Y. Wang, W. Gu, S. Fu, Y. Li et al., Expression and function of myelin-associated proteins and their common receptor NgR on oligodendrocyte progenitor cells, Brain Research. févr, vol.1437, pp.1-15, 2012.

M. Domeniconi, Z. Cao, T. Spencer, R. Sivasankaran, K. C. Wang et al., MyelinAssociated Glycoprotein Interacts with the Nogo66 Receptor to Inhibit Neurite Outgrowth, Neuron. juill, vol.35, issue.2, pp.283-90, 2002.

L. Mckerracher, Identification of Myelin-Associated Glycoprotein as a Major Myelin-berived Inhibitor * n of Neurite Growth, Neuron, vol.7, 1994.

G. Montag, . Bartsch, and . Montag, pdf. Neuron, 1994.

C. Li and M. Tropak, Myelination in the absence of myelin associated glyocoprotein, Nature, 1994.

S. Monaco, B. Bonetti, and S. Ferrari, Complement dépendaent demyelination in patients with IgM monoclonal gammapathy and polyneuropathy, N Engl J Med

M. Takatsu, A. P. Hays, N. Latov, G. M. Abrams, R. Nemni et al., Immunofluorescence study of patients with neuropathy and IgM M proteins, vol.18, pp.173-81, 1985.

L. H. Van-den-berg, A. P. Hays, E. Nobile-orazio, L. J. Kinsella, E. Manfredini et al., AntiMAG and anti-SGPG antibodies in neuropathy, Muscle & Nerve. mai, vol.19, issue.5, pp.637-680, 1996.

M. Weiss, M. Dalakas, C. Lauter, H. Willison, and R. Quarles, Variability in the binding of antiMAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IgM paraproteinemia, Journal of Neuroimmunology. mars, vol.95, issue.1-2, pp.174-84, 1999.

R. Mcgarry, S. Helfand, and R. Quarles, Recognition of myelin-associated glycoprotein by the monoclonal antibody HNK-1, Nature, 1983.

T. Maisonobe, B. Chassande, M. Verin, M. Jouni, J. M. Leger et al., Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients, Neurosurgery & Psychiatry. 1 juill, vol.61, issue.1, pp.36-42, 1996.

P. G. Bain, T. C. Britton, I. H. Jenkins, P. D. Thompson, J. C. Rothwell et al., Tremor associated with benign IgM paraproteinaemic neuropathy, Brain, vol.119, issue.3, pp.789-99, 1996.
DOI : 10.1093/brain/119.3.789

URL : https://academic.oup.com/brain/article-pdf/119/3/789/1113136/119-3-789.pdf

J. Svahn, P. Petiot, J. Antoine, C. Vial, E. Delmont et al., Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features, Neurosurgery & Psychiatry. mai, vol.89, issue.5, pp.499-505, 2018.

L. Magy, R. Kaboré, S. Mathis, P. Lebeau, K. Ghorab et al., Heterogeneity of Polyneuropathy Associated with Anti-MAG Antibodies, Journal of Immunology Research, vol.2015, pp.1-9, 2015.

M. Luigetti, A. Conte, N. Montano, D. Grande, A. Madia et al., Clinical and pathological heterogeneity in a series of 31 patients with IgM-related neuropathy, Journal of the Neurological Sciences. août, vol.319, issue.1-2, pp.75-80, 2012.

E. K. Vanhoutte, C. G. Faber, and I. Merkies, ENMC international workshop: Outcome measures in inflammatory peripheral neuropathies 8-10, vol.23, pp.924-957, 2013.
DOI : 10.1016/j.nmd.2013.06.006

URL : https://doi.org/10.1016/j.nmd.2013.06.006

E. Nobile-orazio, N. Meucci, L. Baldini, A. D. Troia, and G. Scarlato, Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies

G. Galassi, M. Tondelli, A. Ariatti, F. Benuzzi, P. Nichelli et al., Long-term disability and prognostic factors in polyneuropathy associated with anti-myelin-associated glycoprotein (MAG) antibodies, International Journal of Neuroscience, vol.127, issue.5, pp.439-486, 2017.
DOI : 10.1080/00207454.2016.1191013

J. S. Katz, D. S. Saperstein, G. Gronseth, A. A. Amato, and R. J. Barohn, Distal acquired demyelinating symmetric neuropathy, Neurology. 8 févr, vol.54, issue.3, pp.615-615, 2000.
DOI : 10.1212/wnl.54.3.615

D. A. Kaku, J. D. England, and A. J. Sumner, Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucurohyl paragloboside, vol.7, 1994.

S. Attarian, J. P. Azulay, J. Boucraut, N. Escande, and J. Pouget, Terminal latency index and modi®ed F ratio in distinction of chronic demyelinating neuropathies, Clinical Neurophysiology, vol.7, 2001.

M. Capasso, F. Torrieri, A. D. Muzio, M. Angelis, A. Lugaresi et al., Can electrophysiology differentiate polyneuropathy with anti-MAG/SGPG antibodies from chronic inflammatory demyelinating polyneuropathy?, Clinical Neurophysiology, vol.8, 2002.
DOI : 10.1046/j.1529-8027.2002.02032_1.x

A. Gesquière-dando, E. Delmont, M. Launay, J. Boucraut, and S. Attarian, Are electrophysiological features related to disability in patients with anti-MAG neuropathy?, Neurophysiologie Clinique/Clinical Neurophysiology. févr, vol.47, issue.1, pp.75-81, 2017.

, European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision, Journal of the Peripheral Nervous System. mars, vol.15, issue.1, pp.1-9, 2010.

, European Federation of Neurological Societies/Peripheral Nerve Society Guideline* on management of paraproteinemic demyelinating neuropathies, Joint Task Force of the EFNS and the PNS, vol.15, pp.185-95, 2010.

C. Caudie, F. Kaygisiz, P. Jaquet, and P. Petiot, Les autoanticorps IgM anti-MAG par Elisa Bühlmann : apport diagnostique dans 117 neuropathies périphériques auto-immunes associées à une IgM monoclonale à activité anti-SGPG/SGLPG, Ann Biol Clin, vol.64, p.7, 2006.

M. Launay, E. Delmont, C. Benaim, S. Sacconi, C. Butori et al., Les polyneuropathies avec IgM monoclonale anti-MAG : étude descriptive clinique, biologique, électrophysiologique et anatomopathologique d'une cohorte de 13 patients, Revue Neurologique. déc, vol.165, issue.12, pp.1071-1080, 2009.

Y. Kawagashira, H. Koike, M. Tomita, S. Morozumi, M. Iijima et al., Morphological Progression of Myelin Abnormalities in IgM-Monoclonal Gammopathy of Undetermined Significance AntiYMyelin-Associated Glycoprotein Neuropathy, J Neuropathol Exp Neurol, vol.69, issue.11, p.15, 2010.

Y. Kawagashira, H. Koike, M. Tomita, S. Morozumi, M. Iijima et al., Morphological Progression of Myelin Abnormalities in IgM-Monoclonal Gammopathy of Undetermined Significance AntiYMyelin-Associated Glycoprotein Neuropathy, J Neuropathol Exp Neurol, vol.69, issue.11, p.15, 2010.

M. P. Lunn and E. Nobile-orazio, Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies

, Cochrane Database of Systematic Reviews, issue.4, 2016.

. Disponible,

M. C. Dalakas, R. H. Quarles, R. G. Farrer, J. Dambrosia, S. Soueidan et al., A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy, Annals of Neurology, vol.40, issue.5, pp.792-797, 1996.

G. Comi, L. Roveri, A. Swan, H. Willison, M. Bojar et al., A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy, Journal of Neurology, vol.249, issue.10, pp.1370-1377, 2002.

E. Ellie, A. Vital, A. Steck, J. Boiron, C. Vital et al., Neuropathy associated with ?benign? anti-myelin-associated glycoprotein IgM gammopathy: Clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases, Journal of Neurology, vol.243, issue.1, pp.34-43, 1995.

K. C. Gorson, A. H. Ropper, D. H. Weinberg, and R. Weinstein, Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy, Muscle & Nerve. juin, vol.24, issue.6, pp.778-86, 2001.

K. Huang-xuan, J. M. Leger, B. Younes-chennoufi, and A. , Treatment of immune deficient neuropathies with intravenous polyvalent immunoglobulins. An open study of 16 cases, La Revue neurologique, 1993.

J. M. Leger, A. B. Younes-chennoufi, B. Chassande, G. Davila, P. Bouche et al., Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy, Neurosurgery & Psychiatry, vol.57, pp.46-55, 1994.

D. Cook, M. Dalakas, A. Galdi, D. Biondi, and H. Porter, High-dose intravenous immunoglobulins in the treatment of demyelinating neuropathy associated with monoclonal gammopathy, Neurology, 1990.

K. C. Gorson, G. Allam, and A. H. Ropper, Chronic inflammatory demyelinating polyneuropathy: Clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy, Neurology. 1 févr, vol.48, issue.2, pp.321-329, 1997.

E. Oksenhendler, S. Chevret, and J. Leger, Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group, Journal of Neurology

P. Dyck, P. Low, and A. Windebank, Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance, N Engl J Med, 1991.

J. Niermeijer, M. Eurelings, M. W. Van-der-linden, H. M. Lokhorst, H. Franssen et al., Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy, Neurology. 3 juill, vol.69, issue.1, pp.50-59, 2007.

X. Mariette, C. Chastang, J. Louboutin, J. Leger, P. Clavelou et al., A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM, Neurosurgery & Psychiatry. 1 juill, vol.63, issue.1, pp.28-34, 1997.

X. Mariette, J. Brouet, and S. Chevret, A randomised double blind trial versus placebo does not confirm the benefit of á-interferon in polyneuropathy associated with monoclonal IgM, J Neurol Neurosurg Psychiatry

J. Leger, K. Viala, G. Nicolas, A. Creange, J. Vallat et al., Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy, Neurology. 11 juin, vol.80, issue.24, pp.2217-2242, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01085949

M. C. Dalakas, G. Rakocevic, M. Salajegheh, J. M. Dambrosia, A. F. Hahn et al., Placebocontrolled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy, Annals of Neurology. mars, vol.65, issue.3, pp.286-93, 2009.

S. Gazzola, E. Delmont, J. Franques, J. Boucraut, E. Salort-campana et al., Predictive factors of efficacy of rituximab in patients with anti-MAG neuropathy, Journal of the Neurological Sciences. juin, vol.377, pp.144-152, 2017.

R. Iancu-ferfoglia, R. Guimarães-costa, K. Viala, L. Musset, J. Neil et al., Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG followup study: Long-term efficacy of rituximab in IgM, Journal of the Peripheral Nervous System. mars, vol.21, issue.1, pp.10-14, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01285408

E. Delmont, P. Y. Jeandel, C. Benaïm, E. Rosenthal, J. G. Fuzibet et al., Treatment with rituximab in patients with polyneuropathy with anti-MAG antibodies, Journal of Neurology. sept, vol.258, issue.9, pp.1717-1726, 2011.
DOI : 10.1007/s00415-011-5994-0

URL : https://hal.archives-ouvertes.fr/hal-00703179

J. Niermeijer, M. Eurelings, H. L. Lokhorst, W. Van-der-pol, H. Franssen et al., Rituximab for polyneuropathy with IgM monoclonal gammopathy, Neurosurgery & Psychiatry. 1 sept, vol.80, issue.9, pp.1036-1045, 2009.
DOI : 10.1136/jnnp.2008.155325

L. Benedetti, C. Briani, M. Grandis, T. Vigo, M. Gobbi et al., Predictors of response to rituximab in patients with neuropathy and anti?myelin associated glycoprotein immunoglobulin M, Journal of the Peripheral Nervous System. juin, vol.12, issue.2, pp.102-109, 2007.

S. Renaud, P. Fuhr, and M. Gregor, High-dose rituximab and anti-MAG-associated polyneuropathy, Neurology, 2006.
DOI : 10.1212/01.wnl.0000201193.00382.b3

S. Renaud, M. Gregor, P. Fuhr, D. Lorenz, G. Deuschl et al., Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies, Muscle & Nerve. mai, vol.27, issue.5, pp.611-616, 2003.

A. Pestronk, Treatment of IgM antibody associated polyneuropathies using rituximab, Neurosurgery & Psychiatry. 1 avr, vol.74, issue.4, pp.485-494, 2003.

Y. Kawagashira, H. Koike, K. Ohyama, R. Hashimoto, M. Iijima et al., Axonal loss influences the response to rituximab treatment in neuropathy associated with IgM monoclonal gammopathy with anti-myelin-associated glycoprotein antibody, Journal of the Neurological Sciences. janv, vol.348, issue.1-2, pp.67-73, 2015.

N. Al-bustani and M. D. Weiss, Marked and sustained improvement on nerve conduction study of anti-myelin-associated glycoprotein neuropathy following rituximab therapy: Letters to the Editor, Muscle & Nerve. mars, vol.53, issue.3, pp.489-90, 2016.

P. E. Doneddu, M. Kazmi, M. Samuel, M. Mahdi-rogers, and R. Hadden, Deterioration of tremor after treatment with rituximab in anti-MAG neuropathy, Journal of the Neurological Sciences. févr, vol.373, pp.344-349, 2017.

E. Sala, F. Robert-varvat, S. Paul, J. Camdessanché, and J. Antoine, Acute neurological worsening after Rituximab treatment in patients with anti-MAG neuropathy, Journal of the Neurological Sciences, vol.345, issue.1-2, pp.224-231, 2014.
DOI : 10.1016/j.jns.2014.07.055

L. Broglio and G. Lauria, Worsening after rituximab treatment in anti-mag neuropathy, Muscle & Nerve. sept, vol.32, issue.3, pp.378-387, 2005.
DOI : 10.1002/mus.20386

M. Gironi and M. Saresella, Clinical And Immunological Worsening In A Patient Affected With Waldenstrom Macroglobulinemia And Anti-Mag Neuropathy After Treatment With Rituximab, Haematologica, 2006.

A. Stork, N. C. Notermans, A. Vrancken, D. R. Cornblath, and W. Van-der-pol, Rapid worsening of IgM anti-MAG demyelinating polyneuropathy during rituximab treatment: Letter to the Editor, Journal of the Peripheral Nervous System. juin, vol.18, issue.2, pp.189-91, 2013.

G. Blume, A. Pestronk, and L. T. Goodnough, Anti-MAG antibody-associated polyneuropathies: Improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide, Neurology. 1 août, vol.45, issue.8, pp.1577-80, 1995.
DOI : 10.1212/wnl.45.8.1577

N. C. Notermans, H. M. Lokhorst, H. Franssen, Y. Van-der-graaf, L. L. Teunissen et al., Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance, Neurology, vol.47, issue.5, pp.1227-1260, 1996.

H. C. Wilson, M. Lunn, S. Schey, and R. Hughes, Successful treatment of IgM paraproteinaemic neuropathy with fludarabine, Neurosurgery & Psychiatry. 1 mai, vol.66, issue.5, pp.575-80, 1999.

J. Niermeijer, M. Eurelings, and H. L. Lokhorst, Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy, Neurology, 2006.

L. Baldini, E. Nobile-orazio, A. Guffanti, S. Barbieri, M. Carpo et al., Peripheral neuropathy in IgM monoclonal gammopathy and wäldenstrom's macroglobulinemia: A frequent complication in elderly males with low MAG-reactive serum monoclonal component, American Journal of Hematology. janv, vol.45, issue.1, pp.25-31, 1994.

M. Luigetti, F. Madia, A. Conte, P. Tonali, and M. Sabatelli, Neuropathy with Predominant Small Fiber Involvement Associated with Abnormal Anti-MAG Titer, Internal Medicine, vol.49, issue.23, pp.2627-2636, 2010.

Y. Kawagashira, N. Kondo, N. Atsuta, M. Iijima, H. Koike et al., IgM MGUS antiMAG neuropathy with predominant muscle weakness and extensive muscle atrophy, Muscle & Nerve. sept, vol.42, issue.3, pp.433-438, 2010.

Y. A. Rajabally, E. Delmont, F. L. Hiew, A. Aubé-nathier, A. Grapperon et al., Prevalence, correlates and impact of pain and cramps in anti-MAG neuropathy: a multicentre European study, European Journal of Neurology. janv, vol.25, issue.1, pp.135-176, 2018.

C. Bouchard, C. Lacroix, V. Plante, D. Adams, F. Chedru et al., Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy, Neurology. 1 févr, vol.52, issue.3, pp.498-498, 1999.

E. Delmont, ENMG des neuropathies anti-MAG : intérêt diagnostique et corrélations cliniques, Neurophysiologie Clinique/Clinical Neurophysiology. juin, vol.47, issue.3, p.197, 2017.

M. C. Dalakas, G. Rakocevic, M. Salajegheh, J. M. Dambrosia, A. F. Hahn et al., Placebocontrolled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy, Annals of Neurology. mars, vol.65, issue.3, pp.286-93, 2009.

L. Benedetti, E. Zardini, C. Briani, A. Beronio, S. Gastaldi et al., B-cell-activating factor in rituximab-treated patients with anti-MAG polyneuropathy, Neurosurgery & Psychiatry, vol.82, issue.11, pp.1291-1295, 2011.

G. Galassi, M. Tondelli, A. Ariatti, F. Benuzzi, P. Nichelli et al., Long-term disability and prognostic factors in polyneuropathy associated with anti-myelin-associated glycoprotein (MAG) antibodies, International Journal of Neuroscience, vol.127, issue.5, pp.439-486, 2017.